ArticlePloS one2026
Anti-inflammatory activity and metabolite profiling of myo-inositol in LPS-stimulated macrophages.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploratory evaluation of candidate metabolites identified in Clonorchis sinensis preparations in psoriasis-like inflammatory models.Parasites, hosts and diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There has been increasing interest in using dietary bioactive substances to alleviate and reduce inflammation. This study aims to assess myo-inositol's possible anti-inflammatory effects, especially in handling conditions associated with macrophage activity. In this context, myo-inositol coated with polyethylene glycol (PEG) was created as a drug delivery system, and the macrophage cell line RAW 264.7 was used to evaluate its cytotoxicity. Additionally, their ability to suppress pro-inflammatory gene expressions induced by lipopolysaccharide (LPS) was investigated by determining the expression of pro-inflammatory genes such as interleukin (IL)-6, IL-1β, and tumor necrosis factor (TNF)-α. Furthermore, the molecular mechanisms and metabolic pathways affected by myo-inositol treatment were evaluated using a mass spectrometry-based metabolomics approach. PEGylated myo-inositol exhibited slight toxicity against RAW 264.7 cells with IC50 values 124.9 μg/ml. However, myo-inositol did not exhibit toxicity over RAW 264.7 cells. In LPS-stimulated RAW 264.7 cells, PEGylated myo-inositol at concentrations of 31.2 and 15.6 μg/ml significantly reduced the expression of pro-inflammatory cytokines IL-6, IL-1β, and TNF-α at both the mRNA and protein levels. Moreover, PEGylated myo-inositol at 31.2 μg/mL reduced nitric oxide (NO) production by approximately 11.5-fold compared to the LPS group, further supporting its anti-inflammatory and immunomodulatory potential. The Metabolomics study identified 156 metabolites and revealed that the PEGylated myo-inositol significantly altered the metabolic profile of RAW 264.7 compared to the LPS-stimulated RAW 264.7. Metabolomics showed that the treatment alters the level of metabolites involved in the essential process of pro-inflammatory macrophages including energy metabolisms (e.g., TCA cycle, fatty acid oxidation), amino acids metabolisms (e.g., arginine and tyrosine), pyrimidine and purine metabolism, and lipids metabolism (e.g., 8,11,14-eicosatrienoic acid, sphinganine). Hence, PEGylated myo-inositol reversed some of the LPS impacts. Our Findings indicate that PEGylated myo-inositol exerts a promising anti-inflammatory effect through variant pathways. This can assist in developing the use of PEGylated myo-inositol for inflammatory diseases.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.